CD8A and neoplasm: Anti-PD-1 and anti-PD-1L monoclonal antibodies, better known as immune CPIs, disrupt the PD-1/PD-L1 interaction and result in a directed CD8+ CTL response against PD-L1-positive tumor cells [33].